|
"ou x"的相關文件
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2023 |
Reversible Li Intercalation in Layered Cathodes Enabled by Dopant-Induced Medium-Range Orders
|
Ou, X.;Luo, J.;Zhang, J.;Chen, Chen C.-L.;Yu, J.;Hu, J.;Chang, Chang C.-K.;Moudrakovski, I.;Lau, V.W.;Zhao, R. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
|
